Page 95 - 2018_10-Haematologica-web

Everolimus added to consolidation therapy for AML
Mandeville Hospital: Helen Eagleton; Sunderland Royal Hospital: Annette Nicolle, Scott Marshall; Taunton and Somerset Foundation Trust: Sarah Allford; The Newcastle upon Tyne NHS Foundation Trust: Gail Jones, Graham Jackson; University College London Hospitals: Anthony Goldstone, Asim Khwaja, Kirit Ardeshna, Nishal Patel; University Hospital Aintree: Barbara Hammer, Walid Sadik; University Hospital Coventry and Warwickshire NHS Trust: Mekkali Narayanan, Nicholas Jackson, Peter Rose, Syed Bokhari; University
Hospital of North Staffordshire NHS Trust: Andrew Stewart, Kamaraj Karunanithi, Neil Phillips, Srinivas Pillai; University Hospital of North Tees and Hartlepool: Zor Maung; University Hospital of Wales: Jonathan Kell, Steve Knapper; Victoria Hospital NHS Fife: Stephen Rogers; Waikato Hospital: Hugh Goodman, Humphrey Pullon; Wellington Hospital: John Carter; Western General Hospital: Peter Johnson, Ph Roddie, Annielle Hung; Worcestershire Royal Hospital: Juliet Mills; Worthing Hospital: Santosh Narat.
References
1. Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102(5):865-873.
2. Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML N Engl J Med. 2016; 374(5):422-433.
3. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consol- idation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):586-595.
4. Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S. Mammalian target of rapamycin: a central node of complex signaling cas- cades. Int J Clin Exp Pathol. 2011;4(5):476- 495.
5. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21-35.
6. Park S, Chapuis N, Tamburini J, et al. Role of the PI3K/AKT and mTOR signaling path- ways in acute myeloid leukemia. Haematologica. 2010;95(5):819-828.
7. Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005;105(6):2527- 2534.
8. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid
leukemia cells requires PI3 kinase activation.
Blood. 2003;102(3):972-980.
9. Xu Q, Thompson JE, Carroll M. mTOR reg-
ulates cell survival after etoposide treatment in primary AML cells. Blood. 2005;106(13):4261-4268.
10. Luger S, Perl A, Kemner A, et al. A phase I dose escalation study of the mTOR inhibitor sirolimus and MEC chemotherapy targetting signal transduction in leukemic stem cells for acute myeloid leukemia. Blood. 2006;108(11):161.
11. Perl AE, Kasner MT, Tsai DE, et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res. 2009;(15):6732-6739.
12. Burnett AK, Hills RK, Wheatley K, et al. A sensitive risk score for directing treatment in younger patients with AML Blood. 2006; 108(11):18.
13. Knapper S, Russell N, Gilkes A, et al. A ran- domized assessment of adding the kinase inhibitor lestaurtinib to first-line chemother- apy for FLT3-mutated AML. Blood. 2017; 129(9):1143-1154.
14. Early Breat Cancer Trialists Collaborative Group (EBCTCG). Treatment of early breast cancer. 1. Worldwide evidence 1985-1990, Oxford University Press, USA, 1990
15. Kaymakcalan,M D., Je Y. Sonpavde G. et al. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. Br J Cancer. 2013;108(12):2478-2484.
16. Daver N, Boumber Y, Kantarjiian H, et al. A Phase l/ll study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Cancer Res. 2015;21(12): 2704-2714.
17. Yee AL, Zeng Z, Konople. Phase I/II study of the mammalian target or rapamycin inhibitor everolimus (RAD001) inn patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006;12(17): 5165-5173.
18. Wei AH, Sadawarte S, Catalono J. Phase Ib study combining mTOR inhibitor everolimus (RAD001) with low-dose cytara- bine in untreated elderly AML. Blood. 2010;116(21):3299.
19. Levis M, Brown P, Smith BD, et al. Plasma inhibitory activity (PIA): a pharmacodynam- ic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006;108(10):3477-3483.
20. Knapper S, Burnett AK, Littlewood T, et al. A Phase 2 trial of the FLT3 inhibitor lestaur- tinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemothera- py. Blood. 2006;108(10):3262-3270.
21. Amadori S, Stasi R, Martelli AM. Temsirolimus, an mTOR inhibitor, in com- bination with lower-dose clofarabine as sal- vage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML1107) Br J Haematol. 2012;156(2):205-212.
haematologica | 2018; 103(10)
1661